Citius Pharma Gets Nasdaq Extension to Feb 8, 2027 to Regain $1 Bid Compliance
CTXR sits 28% above its 52-week low of $0.469 on light trading volume (0.3× avg).
Summary
Nasdaq granted Citius Pharmaceuticals an extension until February 8, 2027 to regain compliance with the $1.00 minimum bid price rule. The stock continues to trade on Nasdaq while the company evaluates options.
Key Events · Legal and Risk Events · CTXR
-
Nasdaq Extension Granted
Nasdaq granted Citius Pharmaceuticals an extension through February 8, 2027 to regain compliance with the $1.00 minimum bid price rule.
-
Current Price Below Threshold
The stock trades at $0.60, significantly below the $1.00 requirement, and must close at or above $1.00 for ten consecutive business days before the deadline.
-
Delisting Risk Remains
If compliance is not regained by February 8, 2027, Nasdaq will issue a delisting notice, though the company may appeal to a hearings panel.
-
Going Concern Context
The company's Q3 10-Q disclosed a $49.4M nine-month loss and cash runway only to November 2026, heightening the urgency to address the bid price deficiency.
Analysis · CTXR · Life Sciences
Citius Pharmaceuticals received a Nasdaq extension through February 8, 2027 to regain compliance with the $1.00 minimum bid price rule. The stock currently trades at $0.60, well below the threshold, and the company has a going concern warning with cash runway only to November 2026. This extension provides temporary relief but the delisting risk remains acute if the share price does not recover.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 37.5% of the 3434 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTXR was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.5M. The 52-week trading range was $0.47 to $2.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.